Develops immunotherapies for cancer treatment, focusing on enhancing immune responses.
Scinai Immunotherapeutics Ltd., a biopharmaceutical company in its developmental stages, specializes in advancing, producing, and distributing treatments for infectious and autoimmune diseases across Israel. Leveraging strategic partnerships with the Max Planck Society and University Medical Center Göttingen, Scinai focuses on developing nanosized antibodies (NanoAbs), notably for COVID-19 and other disease indications.
Formerly known as BiondVax Pharmaceuticals Ltd., the company rebranded to Scinai Immunotherapeutics Ltd. in September 2023. Since its inception in 2003, Scinai has been headquartered in Jerusalem, Israel, driving innovation in biopharmaceuticals through its commitment to pioneering research and collaborative initiatives.
Scinai Immunotherapeutics Ltd. was founded with a mission to innovate treatments that address critical medical challenges. With a strong emphasis on research and development, the company continues to expand its portfolio of NanoAbs, aiming to deliver effective solutions that improve public health outcomes worldwide.